Terms: = Brain cancer AND CXCR4, D2S201E, 7852, ENSG00000121966, P61073, NPYY3R, NPY3R, HM89, NPYRL, LESTR, HSY3RR, LCR1, fusin, WHIM, NPYR, FB22, CD184 AND Treatment
114 results:
1. Relationship between chemokine/chemokine receptor and glioma prognosis and outcomes: Systematic review and meta-analysis.
Yang S; Luo M; Yang S; Yuan M; Zeng H; Xia J; Wang N
Int Immunopharmacol; 2024 May; 133():112047. PubMed ID: 38631221
[TBL] [Abstract] [Full Text] [Related]
2. Targeting the CXCL12/cxcr4 pathway to reduce radiation treatment side effects.
Chaudary N; Hill RP; Milosevic M
Radiother Oncol; 2024 May; 194():110194. PubMed ID: 38447871
[TBL] [Abstract] [Full Text] [Related]
3. Bone Marrow Stromal Cells inhibited the growth and metastasis of human U87 cells through delivering exosomal miR-506.
Zhang L; Ding Y; Zhou W; Xu X; Zheng J
Medicine (Baltimore); 2023 Dec; 102(49):e36582. PubMed ID: 38065867
[TBL] [Abstract] [Full Text] [Related]
4. Chemokine receptor cxcr4 interacts with nuclear receptor Nur77 and promote glioma invasion and progression.
Dai Y; Yu C; Zhou L; Cheng L; Ni H; Liang W
Brain Res; 2024 Jan; 1822():148647. PubMed ID: 37890573
[TBL] [Abstract] [Full Text] [Related]
5. cxcr4 antagonists disrupt leukaemia-meningeal cell adhesion and attenuate chemoresistance.
Jonart LM; Ostergaard J; Brooks A; Fitzpatrick G; Chen L; Gordon PM
Br J Haematol; 2023 May; 201(3):459-469. PubMed ID: 36535585
[TBL] [Abstract] [Full Text] [Related]
6. Molecular profile reveals immune-associated markers of medulloblastoma for different subtypes.
Chen J; Kang Z; Li S; Wang C; Zheng X; Cai Z; Pan L; Chen F; Li W
Front Immunol; 2022; 13():911260. PubMed ID: 35967388
[TBL] [Abstract] [Full Text] [Related]
7. Defibrotide suppresses brain metastasis by activating the adenosine A2A receptors.
Dong C; Zhu L; Yue X; Sun Z; Wang C; Ye Z; Pan B
Anticancer Drugs; 2022 Nov; 33(10):1081-1090. PubMed ID: 35946567
[TBL] [Abstract] [Full Text] [Related]
8. Identification and characterization of sex-dependent gene expression profile in glioblastoma.
Qin S; Yuan Y; Liu H; Pu Y; Chen K; Wu Y; Su Z
Neuropathology; 2023 Feb; 43(1):72-83. PubMed ID: 35789505
[TBL] [Abstract] [Full Text] [Related]
9. Glioblastoma-associated microglia-derived exosomal circKIF18A promotes angiogenesis by targeting FOXC2.
Jiang Y; Zhao J; Xu J; Zhang H; Zhou J; Li H; Zhang G; Xu K; Jing Z
Oncogene; 2022 Jun; 41(26):3461-3473. PubMed ID: 35637250
[TBL] [Abstract] [Full Text] [Related]
10. Systemic Delivery of an Adjuvant cxcr4-CXCL12 Signaling Inhibitor Encapsulated in Synthetic Protein Nanoparticles for Glioma Immunotherapy.
Alghamri MS; Banerjee K; Mujeeb AA; Mauser A; Taher A; Thalla R; McClellan BL; Varela ML; Stamatovic SM; Martinez-Revollar G; Andjelkovic AV; Gregory JV; Kadiyala P; Calinescu A; Jiménez JA; Apfelbaum AA; Lawlor ER; Carney S; Comba A; Faisal SM; Barissi M; Edwards MB; Appelman H; Sun Y; Gan J; Ackermann R; Schwendeman A; Candolfi M; Olin MR; Lahann J; Lowenstein PR; Castro MG
ACS Nano; 2022 Jun; 16(6):8729-8750. PubMed ID: 35616289
[TBL] [Abstract] [Full Text] [Related]
11. Regorafenib Reverses Temozolomide-Induced CXCL12/cxcr4 Signaling and Triggers Apoptosis Mechanism in Glioblastoma.
Chiang IT; Liu YC; Liu HS; Ali AAA; Chou SY; Hsu TI; Hsu FT
Neurotherapeutics; 2022 Mar; 19(2):616-634. PubMed ID: 35267171
[TBL] [Abstract] [Full Text] [Related]
12. Patient-individual phenotypes of glioblastoma stem cells are conserved in culture and associate with radioresistance, brain infiltration and patient prognosis.
Ganser K; Eckert F; Riedel A; Stransky N; Paulsen F; Noell S; Krueger M; Schittenhelm J; Beck-Wödl S; Zips D; Ruth P; Huber SM; Klumpp L
Int J Cancer; 2022 May; 150(10):1722-1733. PubMed ID: 35085407
[TBL] [Abstract] [Full Text] [Related]
13. C-X-C Chemokine Receptor Type 4-Targeted Imaging in Glioblastoma Multiforme Using
Zhang X; Detering L; Sultan D; Heo GS; Luehmann H; Taylor S; Choksi A; Rubin JB; Liu Y
ACS Appl Bio Mater; 2022 Jan; 5(1):235-242. PubMed ID: 35014818
[TBL] [Abstract] [Full Text] [Related]
14. cxcr4-Directed PET/CT with [
Chen Z; Yang A; Zhang J; Chen A; Zhang Y; Huang C; Chen S; Yao S; Miao W
Mol Imaging Biol; 2022 Jun; 24(3):416-424. PubMed ID: 34651291
[TBL] [Abstract] [Full Text] [Related]
15. The Embryonic Key Pluripotent Factor NANOG Mediates Glioblastoma Cell Migration via the SDF1/cxcr4 Pathway.
Sánchez-Sánchez AV; García-España A; Sánchez-Gómez P; Font-de-Mora J; Merino M; Mullor JL
Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638956
[TBL] [Abstract] [Full Text] [Related]
16. Lung but not brain cancer cell malignancy inhibited by commonly used anesthetic propofol during surgery: Implication of reducing cancer recurrence risk.
Hu C; Iwasaki M; Liu Z; Wang B; Li X; Lin H; Li J; Li JV; Lian Q; Ma D
J Adv Res; 2021 Jul; 31():1-12. PubMed ID: 34194828
[TBL] [Abstract] [Full Text] [Related]
17. New perspectives of quercetin and vitamin C effects on fibronectin-binding integrins and chemokine receptors in prostate cancer cell lines.
Amiri A; Abbasi A; Dehghani M; Ramezani A; Ramezani F; Zal F; Mostafavi-Pour Z
Bratisl Lek Listy; 2021; 122(7):507-512. PubMed ID: 34161119
[TBL] [Abstract] [Full Text] [Related]
18. CD44 loss of function sensitizes AML cells to the BCL-2 inhibitor venetoclax by decreasing CXCL12-driven survival cues.
Yu X; Munoz-Sagredo L; Streule K; Muschong P; Bayer E; Walter RJ; Gutjahr JC; Greil R; Concha ML; Müller-Tidow C; Hartmann TN; Orian-Rousseau V
Blood; 2021 Sep; 138(12):1067-1080. PubMed ID: 34115113
[TBL] [Abstract] [Full Text] [Related]
19. Small interfering RNA (siRNA) to target genes and molecular pathways in glioblastoma therapy: Current status with an emphasis on delivery systems.
Mirzaei S; Mahabady MK; Zabolian A; Abbaspour A; Fallahzadeh P; Noori M; Hashemi F; Hushmandi K; Daneshi S; Kumar AP; Aref AR; Samarghandian S; Makvandi P; Khan H; Hamblin MR; Ashrafizadeh M; Zarrabi A
Life Sci; 2021 Jun; 275():119368. PubMed ID: 33741417
[TBL] [Abstract] [Full Text] [Related]
20. cxcr4 antagonism sensitizes cancer cells to novel indole-based MDM2/4 inhibitors in glioblastoma multiforme.
Daniele S; La Pietra V; Piccarducci R; Pietrobono D; Cavallini C; D'Amore VM; Cerofolini L; Giuntini S; Russomanno P; Puxeddu M; Nalli M; Pedrini M; Fragai M; Luchinat C; Novellino E; Taliani S; La Regina G; Silvestri R; Martini C; Marinelli L
Eur J Pharmacol; 2021 Apr; 897():173936. PubMed ID: 33581134
[TBL] [Abstract] [Full Text] [Related]
[Next]
